Frazor Titus Edmondson III Sells 4,369 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Frazor Titus Edmondson III sold 4,369 shares of Zai Lab stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $156,803.41. Following the completion of the transaction, the insider now owns 27,217 shares of the company’s stock, valued at approximately $976,818.13. This trade represents a 13.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Frazor Titus Edmondson III also recently made the following trade(s):

• On Friday, February 28th, Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock. The stock was sold at an average price of $32.98, for a total value of $479,661.12.

Zai Lab Stock Performance

ZLAB traded up $0.26 during trading on Thursday, reaching $36.69. The company’s stock had a trading volume of 1,224,785 shares, compared to its average volume of 772,741. The company’s fifty day moving average price is $32.39 and its 200-day moving average price is $28.64. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.77. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of -13.25 and a beta of 1.07.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analysts’ expectations of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Equities analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on ZLAB shares. Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 target price on the stock. Bank of America restated a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Thursday, March 27th. Finally, JPMorgan Chase & Co. upped their price target on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, March 13th.

Institutional Investors Weigh In On Zai Lab

Institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in Zai Lab in the 4th quarter valued at about $29,000. Public Employees Retirement System of Ohio lifted its stake in shares of Zai Lab by 20.8% during the fourth quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock valued at $484,000 after buying an additional 3,179 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after purchasing an additional 1,200 shares during the last quarter. Woodline Partners LP grew its holdings in Zai Lab by 9.4% in the 4th quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock valued at $46,089,000 after buying an additional 151,835 shares during the period. Finally, Vestal Point Capital LP acquired a new position in Zai Lab during the fourth quarter worth approximately $7,857,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.